Get the Stockscreener App
7.10
1.21%
0.085
Capricor Therapeutics Inc stock is traded at $7.10, with a volume of 888.71K.
It is up +1.21% in the last 24 hours and up +8.90% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$7.015
Open:
$7.03
24h Volume:
888.71K
Relative Volume:
0.35
Market Cap:
$324.59M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-8.5542
EPS:
-0.83
Net Cash Flow:
$-33.33M
1W Performance:
-10.80%
1M Performance:
+8.90%
6M Performance:
-52.67%
1Y Performance:
+55.02%
1-Day Range:
$6.92
$7.2992
1-Week Range:
$6.9007
$7.9999
52-Week Range:
$3.98
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
7.10 | 352.02M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
CAPR Investors Have the Opportunity to Lead the Capricor Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - FinancialContent
Best data tools to analyze Capricor Therapeutics Inc. stockBear Alert & Verified Swing Trading Watchlists - Newser
Leading vs lagging indicators on Capricor Therapeutics Inc. performance - Newser
Published on: 2025-08-20 02:01:26 - Newser
Technical analysis overview for Capricor Therapeutics Inc. stock2025 Volatility Report & Real-Time Market Trend Scan - Newser
Applying big data sentiment scoring on Capricor Therapeutics Inc.Quarterly Trade Review & Accurate Trade Setup Notifications - Newser
Published on: 2025-08-19 23:32:36 - Newser
How to build a custom watchlist for Capricor Therapeutics Inc.2025 Volatility Report & Weekly Top Gainers Trade List - Newser
Is Capricor Therapeutics Inc. forming a reversal patternMarket Growth Review & Low Risk Entry Point Tips - Newser
Real time alert setup for Capricor Therapeutics Inc. performanceJuly 2025 Trends & Consistent Profit Trade Alerts - Newser
CAPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Capricor Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025CAPR - Morningstar
Published on: 2025-08-19 05:33:56 - Newser
What the charts say about Capricor Therapeutics Inc. todayJuly 2025 Recap & Accurate Buy Signal Notifications - Newser
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Capricor Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 15, 2025 Deadline to file Lead Plaintiff Motion - GlobeNewswire
Capricor Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 15, 2025 Deadline to file Lead Plaintiff Motion - GlobeNewswire Inc.
Capricor Therapeutics, Inc. Securities Fraud Class Action - GlobeNewswire
Capricor Initiates First-in-Human Trial of StealthX™ Vaccine Under NIAID’s Project NextGen - Quiver Quantitative
Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine - GlobeNewswire
Shareholders that lost money on Capricor Therapeutics, Inc.(CAPR) should contact The Gross Law Firm about pending Class ActionCAPR - PR Newswire
SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces A - GlobeNewswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
What makes Capricor Therapeutics Inc. stock price move sharplyGap Up & Low Risk High Win Rate Stock Picks - Newser
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. – CAPR - FinancialContent
Price action breakdown for Capricor Therapeutics Inc.Long Setup & Detailed Earnings Play Alerts - Newser
Momentum divergence signals in Capricor Therapeutics Inc. chartQuarterly Profit Review & AI Powered Market Entry Ideas - Newser
Live market analysis of Capricor Therapeutics Inc.Rate Hike & Technical Confirmation Trade Alerts - Newser
When is the best time to exit Capricor Therapeutics Inc.July 2025 Big Picture & Smart Allocation Stock Tips - Newser
Bragar Eagel & Squire, P.C. Urges Investors in XPLR - GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Investors in XPLR Infrastructure, Centene, Biohaven, or Capricor to Inquire About Their Rights in Class Action Lawsuits - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure ... - Eagle-Tribune
Custom watchlist performance reports with Capricor Therapeutics Inc.Long Setup & Safe Capital Growth Stock Tips - Newser
Published on: 2025-08-16 02:13:07 - Newser
Published on: 2025-08-15 23:36:43 - beatles.ru
Capricor Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationCAPR - WV News
Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025CAPR - The Malaysian Reserve
Capricor Therapeutics shares rise 2.19% premarket after the announcement of the Second Quarter 2025 Conference Call. - AInvest
CAPR FY2025 EPS Estimate Lowered by Cantor Fitzgerald - Defense World
HC Wainwright Issues Pessimistic Estimate for CAPR Earnings - Defense World
Roth Capital Has Bearish Estimate for CAPR Q3 Earnings - Defense World
Class Action Lawsuit Filed Against Capricor Therapeutics, Inc. (CAPR)Recover LossesContact Levi & Korsinsky Before September 15, 2025 - ACCESS Newswire
Transcript : Capricor Therapeutics, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Levi & Korsinsky Notifies Shareholders of Capricor Therapeutics, Inc.(CAPR) of a Class ... - Bluefield Daily Telegraph
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Capricor Therapeutics, Inc.(CAPR) Shareholders - Morningstar
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Capricor Therapeutics Inc Stock (CAPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Mar 03 '25 |
Option Exercise |
1.39 |
2,500 |
3,475 |
8,223 |
| Litvack Frank | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
25,000 |
34,750 |
132,382 |
| DUNBAR GEORGE W JR | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
11,306 |
| COLLIER EARL M JR | Director |
Feb 27 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
57,606 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Dec 13 '24 |
Option Exercise |
1.39 |
8,000 |
11,120 |
28,047 |
| Litvack Frank | Director |
Dec 03 '24 |
Option Exercise |
1.10 |
20,391 |
22,430 |
46,278 |
| Nippon Shinyaku Co Ltd | 10% Owner |
Sep 20 '24 |
Buy |
5.36 |
2,798,507 |
14,999,998 |
7,090,351 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):